This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Related: Genentech’s New Ocular Implant DrugDelivery System for Macular Degeneration Could Be a Game Changer. We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia. Vuity is available by prescription.
It is not necessary to use a spacer with Fostair inhaler; however, spacers improve drugdelivery in patients with poor coordination. A spacer may offer drugdelivery benefits in a wider patient group. Doctors can prescribe medicines outside their license; however, licensed drugs are mostly the first choice.
Certain procedures like targeting a chemical combination that might be optimum to create a drug, reducing human time is crucial aid to drug discovery. Nowadays this process is achieved by AI and machine learning , leading to immense support in drug development. Supercomputers are one such example. Nanotechnology.
“Doctors often treat patients who have rheumatoid arthritis with injections or infusions of anti-inflammatory biologic drugs, but those drugs can cause significant side effects when delivered long enough and at high enough doses to have beneficial effects,” said senior investigator Farshid Guilak, PhD, the Mildred B. .
At the moment, Herceptin is available as a subcutaneous injection but Perjeta needs to be delivered by intravenous infusion – a process that takes hours – and Roche says that means Phesgo is preferred by both patients and doctors and also reduces the cost of treatment.
New DrugDelivery Methods New drugdelivery methods can help improve patient outcomes and reduce side effects, In addition, these methods can also increase patient adherence to medication regimens.
They offer several advantages over traditional drugdelivery systems ( such as vials and syringes ), including reduced chances of dosing errors, increased patient compliance and decreased risk of microbial contamination. Prefilled syringes are syringes that come pre-filled with a specific dose of medication.
Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drugdelivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.
Dr. Bokhari has a Doctor of Medicine degree from the University of Punjab, Rawalpindi Medical College, and an Executive MBA from Temple University, Fox School of Business & Management. Bokhari: Medicus Pharma, through its subsidiary SkinJect, addresses these needs with its innovative transdermal drugdelivery system (TDDS).
It is co-formulated with recombinant hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drugdelivery technology. The drug is not indicated or recommended for patients with light chain amyloidosis who have NYHA Class IIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials.
The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. However, most doctors polled by IQVIA consistently state that whilst they are happy to manage many aspects of patient care remotely where possible, they want to see the patient face-to-face to prescribe a newly launched medicine.
Achieving hematologic complete response is an important treatment goal, and today’s approval based on this clinical endpoint will provide doctors and the larger medical community with a new option to treat newly diagnosed patients.”. Davis Myeloma and Amyloid Program, Tufts Medical Center, and ANDROMEDA study investigator.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content